Mast Cell Tumors Flashcards

1
Q

Where do mast cells arise from? What are 4 functions?

A

BM hematopoietic precursors under the influence of stem cell factor

  1. wound healing
  2. induction of innate immune response
  3. antiparasite activity
  4. modulation of reaction to insect and spider venoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What 4 substances are found in the granules of mast cells?

A
  1. heparin - bruising
  2. histamine - irritation, ulceration
  3. TNFa
  4. proteases - chymase, tryptase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the most common cutaneous tumor? What are some breeds with predisposition?

A

mast cell tumors

  • Bulldogs
  • Labs
  • Goldens
  • Cockers
  • Schnauzers
  • Pitbulls
  • Beagles
  • Shar-Peis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do mast cell tumors arise?

A

normal KIT receptor for stem cell factor become dysregulated and aberrantly located, leading to abnormal growth and aggressive biologic tendencies

  • stem cell factor independent activation and unregulated KIT signal transduction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are common locations of MCTs?

A
  • conjunctiva (benign)
  • nasopharynx
  • larynx
  • oral cavity (malignant)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How are MCTs commonly diagnosed? Graded? Staged?

A

cytology - Wright-Giemsa or toluidine blue can stain granules when Romanowsky stains fail

histopathology with IHC of vimentin, tryptase, and CD117 (for KIT)

abdominal U/S, three-view chest radiographs, LN evaluation, BM cytology, buffy coat more useful in cats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is a more accurate indication of mast cell tumor metastasis through lymph nodes?

A

clustering and aggregates —> most likely need to remove node for histologic confirmation

  • mast cells are normally found in LNs in smaller amounts and can increase in the presence of infection and ulceration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the 4 stages of MCTs according to the Weishaar Nodal Classification System?

A
  1. HN0 - no metastasis
  2. HN1 - pre-metastatic
  3. HN2 - early metastasis
  4. HM3 - overt metastasis

HN2 and HN3 are clinically relevant with decreased MST

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When is U/S guided aspiration of liver and spleen indicated for staging MCTs?

A

only if they seem abnormal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some prognostic factors affecting MCTs?

A
  • histologic grade
  • clinical stage
  • location - SQ, conjunctival > oral, sublingual, MM preputial, scrotal, muzzle
  • cell proliferation rate - mitotic index (MI), AgNOR, Ki67
  • recurrence
  • systemic signs
  • breed - brachycephalic > Shar-Peis
  • tumor size - bigger = harder to get good margins
  • C-kit mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the 3 grades of the Patnaik grading scheme?

A
  • Grade I = well-differentiated, 80-100% survival with surgery
  • Grade II = 44%
  • Grade III = 6-7%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is a new method of grading MCTs? How is this becoming difficult?

A

2 tiered - high vs low grade

  • Grade II tumors have been classified as low-grade (16.5%) and high-grade (83.5%) and using the 2-tiered system did not seem to overcome this issue
  • there have been high numbers of Grade II tumors not being cured with wide excision and new targeted chemotherapy drugs are being introduced
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the most common treatments that lead to a cure of Grade II (less than 4 cm) MCTs?

A

surgical excision alone with appropriate margins

  • must be non-metastatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the point of the mast cell tumor proliferation panel? What 4 proteins are evaluated?

A

provides and objective way of grading Grade II MCTs to determine if additional systemic therapy is required after adequate local control

  1. Ki67 (IHC) - proliferation marker only located in dividing cells
  2. AgNORs - indicative of cell turn over (protein synthesis)
  3. KIT (IHC) - location within cell
  4. C-kit mutational status (PCR)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are implication of positives seen on the MCT panels? What treatment will they require?

A
  • high AgNOR and Ki67 indicate high proliferation rate = chemotherapy
  • abnormal localization of KIT = targeted Palladia
  • C-kit mutation positive = targeted Palladia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are 4 treatment options for MCTs?

A
  1. surgery
  2. radiation - definitive or palliative coarse fractionated
  3. chemotherapy - Vinblastine, Lomustine (CCNU)
  4. small-molecule targeted therapy - Palladia (toceranib phosphate)
17
Q

What margins are preferred for excision of MCTs?

A

proportional margins based on the widest diameter + one well-defined fascial plane (clean margin = >1mm)

  • 1.5 cm length = 1.5 cm margin
  • 6 cm length = 6 cm margin
18
Q

What can be added to the treatment plan to decrease recurrence rates of Grade II MCTs following surgical removal?

A

neoadjuvant prednisone until size decreases to one good enough for clean margins

19
Q

What treatment is recommended for Grade II MCTs with lymph node metastasis?

A

surgical removal with removal of metastatic lymph node to increase survival

  • overall, regional LN status does not predict survival in dogs with Grade II MCTs
20
Q

What treatment is recommended for SQ MCTs?

A

surgical excision

  • tend to behave less aggressively than dermal variety due to the fat surrounding it creating a barrier
21
Q

When is definitive radiation therapy recommended for MCTs? What treatment plan is recommended?

A

areas where total excision is not an option, like the distal antebrachium

Mon-Fri daily treatments for a total of 18 treatments (3gy x 18 = 54gy)

22
Q

How does the result of definitive radiation therapy compare in incompletely excised Grade II MCTs, Grade II MCTs with LN metastasis, and Grade III MCTs?

A

~90% disease free 1-5 years with survival 2-5 years (median disease free interval = 54 months)

radiation therapy to primary site and regional lymph node = median disease free interval of 1240 days

median duration of remission = 27.7 months, MST = 28 month

23
Q

How often is coarse fractionated radiation therapy given? In what cases is it recommended? What is commonly added?

A

8gy x 4 doses = MST of 1872

when Prednisone and surgery do not work

Palladia

24
Q

What 4 pre-meds are recommended before starting chemotherapy for MCTs?

A
  1. Prednisone
  2. Diphenhydramine (Benadryl) - blocks H1 receptors
  3. Famotidine - blocks H2 receptors
  4. Omeprazole - recommended for large tumor burdens to avoid GI ulceration
25
Q

What 3 combinations of chemotherapies are used for MCTs? What else is commonly added?

A
  1. Vinblastine - 47% response (MST = 154 days)
  2. Vinblastine + Cyclophosphamide - MST = 145 days
  3. CCNU - 42% response (MST = 79 days)

Palladia - 40% shrinkage, 60% biologically stable disease

26
Q

When is adjuvant chemotherapy recommended? What is commonly used?

A

higher risk Grade II MCT with LN metastasis or location at mucocutaneous junctions / Grade III MCTs

Vinblastine/Prednisone

27
Q

What is Palladia? What 3 results does it action end in?

A

small molecule receptor tyrosine kinase inhibitor - blocks VEGFR-2 (blood vessels), PDGFR, and KIT (on mast cell)

  1. blocks ATP binding site in receptors, which blocks phosphorylation and downstream signal transduction of KIT = stops proliferation
  2. inhibits tumor angiogenesis
  3. regulatory T-cell inhibition
28
Q

What is mutated KIT associated with in mast cells? How does this occur?

A

higher chance of recurrence and metastasis

internal tandem duplication of exons 11 or 12, resulting in a constantly turned on KIT, leading to autophosphorylation without presence of stem cell factor —> continuous proliferation

29
Q

What is Palladia labeled for use in? What response is expected?

A

recurrent Grade II or III canine mast cell tumors with or without LN metastasis

  • objective response = 42.8%
  • biologic response = 59.5%
30
Q

What 5 adverse effects are expected with the use of Palladia? When should it not be given?

A
  1. diarrhea
  2. weight loss
  3. hematochezia, melena
  4. neutropenia
  5. lameness

on the same day as NSAIDs or steroids - avoids GI upset

31
Q

How can the adverse effects of Palladia be managed?

A
  • drug holiday/discontinuation
  • dose reduction
  • change dose frequency
  • supportive medications - Famotidine, Diphenhydramine, Omeprazole, Sucralfate, Cerenia, ONdansetron, Metoclopramide, Metronidazole, Loperamide
32
Q

How do feline MCTs compare to canine MCT?

A
  • multiple, benign cutaneous MCT common
  • no established histologic grading —> well-differentiated vs. anaplastic may have prognostic significance
  • staged with abdominal U/S and chest radiographs
33
Q

What are the 2 most common visceral MCTs seen in cats?

A
  1. splenic
  2. GI
34
Q

How do most cats present with splenic MCTs? What treatment is recommended?

A
  • typical differential for splenic disease + involvement of other organs (liver, LNs, BM, and blood common)
  • concurrent cutaneous involvement not common

surgery (splenectomy) even in the face of disseminated disease + post-op Palladia, since most cats have active mutations in c-kit

(MST = 1-1.5 years)

35
Q

What is the prognosis of feline GI MCT like? What treatment is recommended?

A

poor - high metastatic rate at the time of diagnosis (>80%, MST = 2 months to 1.5 years)

  • NO DISSEMINATION = surgery + post-op adjuvant chemotherapy or targeted therapy
  • DISSEMINATION = chemotherapy/targeted therapy